Kinnate Biopharma Inc.

NasdaqGS:KNTE Stock Report

Mkt Cap: US$348.9m

We’ve recently updated our valuation analysis.

Kinnate Biopharma Valuation

Is KNTE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KNTE?

Other financial metrics that can be useful for relative valuation.

KNTE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-0.9x
PEG Ration/a

Price to Book Ratio vs Peers

How does KNTE's PB Ratio compare to its peers?

The above table shows the PB ratio for KNTE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average5.2x
AUTL Autolus Therapeutics
2.2x28.4%US$358.2m
HRTX Heron Therapeutics
14.3x56.3%US$321.0m
SVRA Savara
2.4x57.4%US$285.1m
AADI Aadi Bioscience
1.8x50.9%US$306.9m
KNTE Kinnate Biopharma
1.4x5.4%US$348.9m

Price-To-Book vs Peers: KNTE is good value based on its Price-To-Book Ratio (1.4x) compared to the peer average (5.2x).


Price to Earnings Ratio vs Industry

How does KNTE's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.2%
n/an/an/a

Price-To-Book vs Industry: KNTE is good value based on its Price-To-Book Ratio (1.4x) compared to the US Biotechs industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is KNTE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KNTE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate KNTE's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of KNTE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate KNTE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate KNTE's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst KNTE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.90
US$31.88
+303.5%
31.5%US$46.00US$11.00n/a8
Jan ’24US$6.10
US$31.88
+422.5%
31.5%US$46.00US$11.00n/a8
Dec ’23US$7.75
US$31.88
+311.3%
31.5%US$46.00US$11.00n/a8
Nov ’23US$8.60
US$35.25
+309.9%
16.1%US$46.00US$29.00n/a8
Oct ’23US$11.95
US$35.25
+195.0%
16.1%US$46.00US$29.00n/a8
Sep ’23US$14.71
US$35.25
+139.6%
16.1%US$46.00US$29.00n/a8
Aug ’23US$9.86
US$35.13
+256.2%
15.7%US$46.00US$29.00n/a8
Jul ’23US$12.75
US$35.43
+177.9%
16.4%US$46.00US$29.00n/a7
Jun ’23US$7.57
US$35.43
+368.0%
16.4%US$46.00US$29.00n/a7
May ’23US$7.47
US$43.43
+481.4%
17.7%US$55.00US$33.00n/a7
Apr ’23US$11.43
US$43.43
+280.0%
17.7%US$55.00US$33.00n/a7
Mar ’23US$7.88
US$44.86
+469.3%
16.9%US$54.00US$33.00n/a7
Feb ’23US$11.30
US$47.57
+321.0%
12.8%US$54.00US$35.00US$7.907
Jan ’23US$17.72
US$47.50
+168.1%
15.4%US$53.00US$32.00US$6.106
Dec ’22US$18.74
US$47.50
+153.5%
15.4%US$53.00US$32.00US$7.756
Nov ’22US$24.79
US$47.00
+89.6%
14.9%US$52.00US$32.00US$8.606
Oct ’22US$24.53
US$47.00
+91.6%
14.9%US$52.00US$32.00US$11.956
Sep ’22US$23.35
US$51.00
+118.4%
2.0%US$52.00US$50.00US$14.714
Aug ’22US$21.58
US$51.00
+136.3%
2.0%US$52.00US$50.00US$9.864
Jul ’22US$23.76
US$51.00
+114.6%
2.0%US$52.00US$50.00US$12.754
Jun ’22US$22.96
US$51.00
+122.1%
2.0%US$52.00US$50.00US$7.574
May ’22US$26.82
US$50.00
+86.4%
3.3%US$52.00US$48.00US$7.473
Apr ’22US$31.12
US$52.50
+68.7%
8.7%US$60.00US$48.00US$11.434
Mar ’22US$34.30
US$52.00
+51.6%
9.4%US$60.00US$48.00US$7.884
Feb ’22US$34.26
US$52.00
+51.8%
9.4%US$60.00US$48.00US$11.304

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies